{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T01:06:33Z","timestamp":1698973593454},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Ebola-Viruserkrankung W\u00e4hrend der durch die Zaire-Virusvariante hervorgerufenen Ebola-Ausbr\u00fcche wurden klinische Studien mit Impfstoffen sowie antiviralen Substanzen durchgef\u00fchrt. Aktuell stehen als Therapie die monoklonalen Antik\u00f6rper Atoltivimab\/Maftivimab\/Odesivimab (kombiniert in Inmazeb) und Ansuvimab (Ebanga) zur Verf\u00fcgung. Zur pr\u00e4ventiven Impfung und zur Pr\u00e4- und Postexpositionsprophylaxe einer Ebola-Virusinfektion (Variante Zaire) sind die Ebola-Zaire-Impfstoffe rVSV\u0394G-ZEBOV-GP, lebend (Ervebo), Ebola-Zaire-Impfstoff Ad26.ZEBOV-GP, rekombinant (Zabdeno) und der Ebola-Impfstoff (MVA-BN-Filo, rekombinant (Mvabea) geeignet.<\/jats:p><jats:p>\n            Marburg-Viruserkrankung Es gibt derzeit kein zugelassenes Medikament zur Behandlung der Marburg-Viruserkrankung. Trotz erheblicher logistischer Schwierigkeiten und der Tatsache, dass die meisten Marburg-Ausbr\u00fcche eher zu klein waren, um Impfstoffstudien zu erm\u00f6glichen, wurden von der WHO 3 Impfstoffkandidaten f\u00fcr eine m\u00f6gliche Studie favorisiert.<\/jats:p>","DOI":"10.1055\/a-1966-9615","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:50:23Z","timestamp":1698969023000},"page":"1437-1442","source":"Crossref","is-referenced-by-count":0,"title":["Ebola-Virus- und Marburg-Viruserkrankung"],"prefix":"10.1055","volume":"148","author":[{"given":"Stefan","family":"Schmiedel","sequence":"additional","affiliation":[{"name":"Sektion Infektiologie, I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Eppendorf (UKE), Hamburg, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Wolf","sequence":"additional","affiliation":[{"name":"Infektiologie, Zentrum f\u00fcr Innere Medizin 2, Klinikum der Johann-Wolfgang Goethe-Universit\u00e4t Frankfurt, Frankfurt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1901594.","article-title":"Ebola","volume":"382","author":"H Feldmann","year":"2020","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"S Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","article-title":"REGN-EB3: first approval","volume":"81","author":"A Markham","year":"2021","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40265-021-01483-4","article-title":"Ansuvimab: first approval","volume":"81","author":"A Lee","year":"2021","journal-title":"Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/trstmh\/trv024","article-title":"Mapping the zoonotic niche of Marburg virus disease in Africa","volume":"109","author":"DM Pigott","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref11","doi-asserted-by":"publisher","article-title":"Callaway E. Marburg virus outbreak: researchers race to test vaccines. Nature 2023; 614: 603.","DOI":"10.1038\/d41586-023-00468-5"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","article-title":"Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial","volume":"401","author":"MJ Hamer","year":"2023","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.22.472410","article-title":"Rapid and durable protection against Marburg virus with a single-shot ChAd3-MARV GP vaccine","author":"R Hunegnaw","year":"2021","journal-title":"bioRxiv"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"SM Jones","year":"2005","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment","volume":"367","author":"KM Daddario-DiCaprio","year":"2006","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274906","article-title":"First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study","author":"V Bockstal","year":"2022","journal-title":"PLOS ONE"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1038\/s41598-023-29517-9","article-title":"Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro","volume":"13","author":"SR Radohitzky","year":"2023","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s41467-021-22132-0","article-title":"Combination therapy protects macaques against advanced Marburg virus disease","volume":"12","author":"RW Cross","year":"2021","journal-title":"Nat Commun"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00874-X","article-title":"Standard of care for viral haemorrhagic fevers (VHFs): a systematic review of clinical management guidelines for high-priority VHFs","author":"I Rigby","year":"2023","journal-title":"Lancet Inf Dis"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1966-9615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:51:14Z","timestamp":1698969074000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1966-9615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":14,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1966-9615","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}